The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Optineurin immunoreactivity in neuronal nuclear inclusions of polyglutamine diseases (Huntington’s, DRPLA, SCA2, SCA3) and intranuclear inclusion body disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have suggested that changes to OPTN are associated with the appearance of inclusion bodies and promote neurotoxicity in various neurodegenerative diseases [28, 71–77].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265 · cited 2×
“OPTN immunoreactivity has been reported in a variety of ubiquitinated inclusions including ALS-associated neuronal cytoplasmic inclusions, neurofibrillary tangles in Alzheimer’s disease, Pick bodies in Pick disease, Lewy bodies in Parkinson’s disease and glial cytoplasmic inclusions in multiple system atrophy [3, 6].”
Background
Research works printed but not linked: 9
- De Marco N, Buono M, Troise F, Diez-Roux G (2006) Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus. J Biol Chem 281:16147–16156 · DOI · Paper page
- Hortobagyi T, Troakes C, Nishimura AL et al (2011) Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol 121:519–527 · DOI
- Ito H, Fujita K, Nakamura M et al (2011) Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol 121:555–557 · DOI
- Okita S, Morigaki R, Koizumi H, Kaji R, Nagahiro S, Goto S (2012) Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington’s disease. Neuroscience 202:363–370 · DOI
- Osawa T, Mizuno Y, Fujita Y, Takatama M, Nakazato Y, Okamoto K (2011) Optineurin in neurodegenerative diseases. Neuropathology 31:569–574 · DOI · Paper page
- Schwab C, Yu S, McGeer EG, McGeer PL (2012) Optineurin in Huntington’s disease intranuclear inclusions. Neurosci Lett 506:149–154 · DOI · Paper page
- Schwab C, Yu S, McGeer PL (2012) Optineurin is colocalized with ubiquitin in Marinesco bodies. Acta Neuropathol 123:289–292 · DOI
- Swarup G, Nagabhushana A (2010) Optineurin, a multifunctional protein involved in glaucoma, amyotrophic lateral sclerosis and antiviral signalling. J Biosci 35:501–505 · DOI
- Takahashi T, Katada S, Onodera O (2010) Polyglutamine diseases: where does toxicity come from? What is toxicity? Where are we going? J Mol Cell Biol 2:180–191 · DOI
Cited by
Compromised autophagy and neurodegenerative diseases
Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3961 · Cited by 851
Autophagy and neurodegeneration
Frake, R. A., Ricketts, T., Menzies, F. M., & Rubinsztein, D. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73944 · Cited by 332
“Optineurin can also bind to protein aggregates (56) and is sequestered in inclusions in ALS patients as well as in other neurodegenerative diseases (57, 58).”
BackgroundThe role of autophagy in axonal degeneration of the optic nerve
Koch, J. C., & Lingor, P. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.08.016 · Cited by 46
Wise, J. P., & Cannon, J. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw133 · Cited by 20
Huang, K.-C., Gomes, C., Shiga, Y., Belforte, N., VanderWall, K. B., Lavekar, S. S., Fligor, C. M., Harkin, J., Hetzer, S. M., Patil, S. V., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01872-2 · Cited by 19
Metadata
- Authors
- Mori, F., Tanji, K., Toyoshima, Y., Yoshida, M., Kakita, A., Takahashi, H., & Wakabayashi, K.
- Venue
- Acta Neuropathologica
- Published
- 2012-02-09
- Volume
- 123
- Issue
- 5
- Pages
- 747-749
- ISSN
- 0001-6322
- 1432-0533
- Cited by
- 36
- References
- 1
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.